Continuous Low Dose of Melphalan and Prednisone in Patients with Multiple Myeloma of Very Old Age or Severe Associated Disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Introduction and Objective
The management of elderly patients with multiple myeloma is a relevant problem because it concerns a great number of patients. Patients with multiple myeloma who are very old or who have severe associated diseases have a dismal outcome. For these patients we retrospectively evaluated the effect of a mild approach with continuous low-dose melphalan and prednisone (cMP).
Design and Methods
109 patients with multiple myeloma, observed between 1985 and 2000, were treated with cMP; 67 were treated at time of diagnosis (group A; median age 78 years) and 42 as a second or subsequent line of therapy (group B; median age 72 years). The toxicity of the treatment was compared with a control group of 29 patients aged over 70 years, treated in the same institution with the conventional cyclical melphalan/prednisone regimen.
Major or minor responses were obtained in 32% of patients in group A and 13% of patients in group B. Disease was stabilised in 45% of group A and 47% of group B and progressed in 5 and 18%, respectively. Median survival was, respectively, 19 and 24 months in group A and B.
Among the 42 patients who received cMP as a second-line therapy (group B), 36 (86%) had previously been treated according to the standard cyclical melphalan/prednisone schedule; of these 12 (33%) obtained a better M protein reduction after cMP compared with the previous response to first-line cyclical melphalan/prednisone.
The cMP schedule was generally well tolerated, and the rate of haematological toxicity was lower than for a historical control group receiving cyclical melphalan/prednisone.
The cMP treatment schedule is well tolerated and results in a high proportion of patients with stable disease, with acceptable survival even in patients with advanced disease.
- Cohen, HJ, Bartolucci, A (1985) Age and treatment of multiple myeloma. Southern Cancer Study Group Experience. Am J Med 79: pp. 316-26 CrossRef
- Attal, MD, Huguet, S, Schlaifer, D (1996) A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: pp. 91-7 CrossRef
- Jagannath, S, Vesole, DH, Glenn, L (1992) Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem support. Blood 80: pp. 1666-72
- Barlogie, B, Jagannath, S, Vesole, D (1995) Autologous and allogenic transplants for multiple myeloma. Semin Hematol 32: pp. 31-44
- Gahrton, G, Tura, S, Ljungman, P (1991) Allogenic bone marrow transplantation in multiple myeloma. N Engl J Med 325: pp. 1267-73 CrossRef
- Barlogie, B, Zangari, M, Spencer, T (2001) Thalidomide in the management ofmultiple myeloma. Semin Hematol 38: pp. 250-9 CrossRef
- Rajkumar, SV, Kyle, RA (2001) Thalidomide in the treatment of plasma cells malignancies. J Clin Oncol 19: pp. 3592-5
- Rodon, P, Linassier, C, Gauvain, JB (2001) Multiple myeloma in elderly patients: presenting features and outcome. Eur J Haematol 66: pp. 11-7 CrossRef
- Kyle, RA (2000) The role of high dose chemotherapy in the treatment of multiple myeloma: a controversy. Ann Oncol 11: pp. 55-8 CrossRef
- Kyle, RA (2001) Management of patients with multiple myeloma: emphasizing the role of high-dose therapy. Clin Lymphoma 2: pp. 21-8 CrossRef
- Oken, MM (1994) Standard treatment of multiple myeloma. Mayo Clin Proc 69: pp. 781-6 CrossRef
- Gregory, WM, Richards, MA, Malpas, JS (1992) Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: pp. 334-42
- Cuzick, J, Erskine, S, Edelman, D (1987) A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. Br J Cancer 55: pp. 523-9 CrossRef
- Oken, MM, Tsiatis, A, Ambramson, N (1984) Comparison of standard (MP) with intensive (VMCP) therapy for the treatment of multiple myeloma. Proc Am Soc Clin Oncol 3: pp. 270
- Oken, MM, Harrington, DP, Abramson, MD (1997) Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, ciclophosphamide and prednisone in the treatment of multiple myeloma. Results of Eastern Cooperative Oncology Group Study. Cancer 79: pp. 1562-7 CrossRef
- Durie, BGM, Salmon, SE (1975) A clinical staging system for multiple myeloma. Cancer 36: pp. 842-54 CrossRef
- Kaplan, EL, Meier, P (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: pp. 457-81 CrossRef
- Singhal, S, Mehta, J, Desikan, R (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: pp. 1565-71 CrossRef
- Dimopoulos, MA, Zervas, K, Kouvatseas, G (2001) Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 12: pp. 991-5 CrossRef
- Barlogie, B, Desikan, R, Eddlemon, S (2001) Extended survival in advanced and refractory multiple myeloma after singleagent thalidomide: identification of prognostic factors in a phase 2 study of 109 patients. Blood 98: pp. 492-4 CrossRef
- Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomised trials. J Clin Oncol 12: pp. 3832-42
- Manoharan, A (2000) Gentle yet effective treatment for elderly patients with refractory or relapsing multiple myeloma. Am J Hematol 65: pp. 81-2 CrossRef
- Continuous Low Dose of Melphalan and Prednisone in Patients with Multiple Myeloma of Very Old Age or Severe Associated Disease
Drugs & Aging
Volume 19, Issue 12 , pp 947-953
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Cellular Biotechnology and Hematology, “La Sapienza” University, Via Benevento 6, 00161, Rome, Italy
- 2. Department of Epidemiology and Biostatistics, Istituto Superiore di Sanità, Rome, Italy